

09. The cost of TB and lung health interventions: methodologies and implications for health systems and patients

**THE 46TH UNION
WORLD CONFERENCE
ON LUNG HEALTH**

CAPE TOWN, SOUTH AFRICA
2-6 DECEMBER 2015

Friday, 04 December 2015, 13:30 - 15:00

Room MR 2.41-2.43

Type of session	Symposium
Track	Advancing the End TB strategy and other policy issues
Track2 (optional)	COPD, asthma and other lung health
Description	In addition to health consequences, tuberculosis (TB) poses serious economic burdens to health systems and patients alike. While the health consequences of TB and lung disease interventions have received considerable attention in conferences and published literature, the analysis of their costs and financial implications has been less prominent. The session will explore the financial implications of alternative TB and lung disease interventions on both the health systems and patients. The focus will be on patient pathways, costing methodologies and catastrophic costs.
Target audience	1. Healthcare professionals, advocates, TB programme implementers and educators
Objectives	<ol style="list-style-type: none"> 1. To provide an overview of current evidence and methodologies in costing TB and lung health interventions 2. To provide examples of costs related to programmatic implementation, health systems and patients. 3. To highlight catastrophic costs incurred by TB patients through the diagnosis and treatment process
Keywords	Health system costs; patient costs; catastrophic costs
Coordinator(s)	Elvis Gama (UK), Jason Madan (UK)
Chair(s)	S. Bertel Squire (UK)
Presentations	<p>13:30 - 13:40 Patient costs for tuberculosis diagnoses in Brazil: comparison of solid and liquid medium culture Afranio Kritski (Brazil)</p> <p>13:45 - 13:55 Modelling the cost-effectiveness for health systems of the Xpert MTB/RIF scale-up by district profile in Tanzania Ivor Langley (UK)</p> <p>14:00 - 14:10 Costing the practical approach to lung health strategy in Malawi Martina Mchenga (Malawi)</p> <p>14:15 - 14:25 The cost of serious adverse events in MDR-TB experience from Ethiopia Mamo Girma (Ethiopia)</p> <p>14:30 - 14:40 Modelling health system costs to support decision making for MDR-TB diagnostics in Cape Town Rory Dunbar (South Africa)</p> <p>14:45 - 15:00 Discussion</p>